Radius Health Announces Engagement With Myrtle Potter & Company for Development of Abaloparatide Commercialization Strategy

Radius Health, Inc.

, a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including metastatic breast cancer, today announced that it has engaged Myrtle Potter & Company, LLC. to support the development of the future global commercial strategy for its lead investigational drug abaloparatide-SC for the potential treatment of post-menopausal osteoporosis. "We are pleased to have the benefit of Myrtle Potter & Company's track record and experience as we prepare to transition Radius from a development stage company to a fully integrated commercial entity. We believe this collaboration will accelerate our disease-awareness efforts to transform the understanding of osteoporosis, which, over the longer term, could help improve the treatment of patients with incident osteoporotic fractures," said Radius Health CEO, Robert E. Ward. "Myrtle and her team's commercial expertise will be a valuable addition to our already strong leadership as we advance our investigational new drug abaloparatide-SC towards regulatory submissions later this year in the U.S. and the EU and prepare for our first potential commercial launch." In June 2015, Radius expects to report the topline 6 month results from the Phase 3 ACTIVExtend trial. These results from ACTIVExtend will be combined with the already completed Phase 3 ACTIVE trial to provide the 24 month data set to be submitted this year to the FDA as a portion of the new drug application ("NDA") for abaloparatide-SC. In December 2014, Radius reported that our Phase 3 (ACTIVE) study evaluating abaloparatide-SC met the primary endpoint (86% reduction in new vertebral fractures versus placebo) as well as key secondary endpoints (43% reduction in non-vertebral fractures versus placebo). Radius is on track for NDA submission to the FDA and MAA submission to EMA by year-end. The National Osteoporosis Foundation (NOF) and the National Bone Health Alliance (NBHA) have highlighted the critical need to improve the screening, diagnosis and treatment for the estimated 2 million Americans who suffer osteoporotic fractures each year. Osteoporosis remains a major unmet medical need as NHBA reports a treatment gap that may impact as many as 80% of these cases. "We have a long history of working with pharmaceutical and biotech companies to maximize the commercial value of their innovative products," said Myrtle Potter, CEO. "We are eager to work with Radius as they seek to launch the first new therapy in many years into the large and growing osteoporosis market, particularly as it may have the potential to benefit the large number of patients at risk of non-vertebral fractures for whom there remains a significant unmet medical need." Founded in 2005 by Myrtle Potter, Myrtle Potter & Company specializes in devising novel strategies to maximize the value of prescription drug brands and portfolios. Prior to founding Myrtle Potter & Company, Myrtle was president and chief operating officer of Genentech for five years, where she led the company's launch of seven products, including the blockbuster cancer therapy Avastin™. Prior to that, Myrtle was president of Bristol-Myers Squibb's $4 billion U.S. Cardiovascular and Metabolic business and led the launch of four drugs, including Plavix™, Pravachol™ and Glucophage™.